Power Law company profile

Amylyx Pharmaceutical

Biotech & Life Sciences · Cambridge, United States · Founded 2014 · IPO 2022 Thoroughbred

Developing new treatments for ALS, Alzheimer's, and all neurodegenerative diseases

Valuation

$1.47B

Market cap · May/2026

Featured in $10B+ revenueThoroughbred · Power Law outcome

Investors

17 investors on Amylyx Pharmaceutical's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 3 investors entered at this stage

Lysosomal Therapeutics

ALS Investment Fund

Morningside

Series B+ 14 investors entered at this stage

Rock Springs Capital

683 Capital

Tybourne Capital Management

Polaris Founders Fund

Marshall Wace

Belinda Termeer

aMoon Fund

Alpha Wave Global

Woodline Partners

Bain Capital Life Sciences

Verition Fund Management

Perceptive Advisors

Viking Global Investors

Avoro Capital Advisors

Global footprint

Where Amylyx Pharmaceutical has talent and traffic

Workforce by country

7 countries with
team presence

🇺🇸 United States91.5%

🇫🇷 France2.4%

🇳🇱 Netherlands1.7%

🇨🇭 Switzerland1.7%

🇩🇪 Germany0.9%

Top 5 of 7 shown

Web traffic by country

13K monthly visits
across markets

🇺🇸 United States88.5%

🇮🇳 India8.5%

🇬🇧 United Kingdom3.1%

🇹🇷 Turkey2.3%

🇵🇰 Pakistan0.8%

Top 5 markets shown

Market sentiment

What the market is saying about Amylyx Pharmaceutical

An AI-synthesized read of the highest-engagement posts about Amylyx Pharmaceutical on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Amylyx Pharmaceutical on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles